Bristol Myers Squibb Company: Too Cheap To Ignore | FAST Graphs

A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market. However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. Despite this low valuation, the company has outperformed the S&P 500 on both dividend income and capital appreciation. Furthermore, this low valuation also supports an opportunity for outsized future gains at below-average levels of risk. In addition to the company's extremely high quality, the significant undervaluation provides a margin of safety as an additional layer of risk mitigation.

In this video, I will be running Bristol Myers Squibb by the numbers via the FAST Graphs fundamentals analyzer software tool. In addition to providing a fundamental analysis of the company, I will simultaneously be illustrating the power of the FAST Graphs research tool as well as how to use it to your maximum benefit.

Try FAST Graphs for FREE:
https://www.fastgraphs.com

SUBSCRIBE To Our YouTube Channel

Disclaimer: FAST Graphs is a tool designed to reveal and present information related to financial data and investment metrics. It is not intended to provide specific advice or recommendations. Instead, it offers a comprehensive view of relevant data, empowering users to make informed decisions based on their own analysis. It's your first step to a more comprehensive research and due diligence process. In short, it is a tool to think with. The opinions in this video are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned.

#dividends #stocks #investing